Full-Time

Senior Director

Quality Control

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$235k - $281kAnnually

Senior

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • BS, MS, or PhD in Chemistry, Pharmaceutical Science, or a related discipline.
  • 15+ years of relevant industry experience in Analytical Development and QC.
  • In-depth knowledge of global and regional regulatory guidelines (FDA, EU, ICH, etc.), particularly in areas such as Quality by Design (QbD), process validation, product launches, commercial manufacturing and post-approval QC requirements.
  • Strong written and verbal communication skills, paired with excellent interpersonal abilities for effective cross-functional collaboration.
  • Extensive knowledge and application of current GMP, coupled with an understanding of best industry practices.
  • Strong problem-solving skills, with a sound ability to make technically driven decisions.
  • Exceptional scientific, business, and technical communication skills, along with strong planning and collaboration capabilities.
  • Proven ability to multi-task and thrive in a fast-paced, innovative environment.
  • Experience and knowledge of global regulatory submissions (e.g., IND, IMPD, NDA, MAA).
Responsibilities
  • Oversee the QC group, provide technical and strategic leadership for day-to-day QC activities supporting clinical and commercial programs. This includes preparing for commercial product launches, managing quality events related to commercial QC testing (e.g., lab investigations for OOS/OOT, deviations, CAPAs).
  • Lead and guide stability program management, quality systems, QC documentation (e.g., SOPs), PAI readiness, and inspections as necessary.
  • Assist in the selection and drive the management of contract organizations (COs), ensuring the effective outsourcing and execution of clinical and commercial QC activities.
  • Author, review, and approve QC-related documentation, including analytical methods, protocols, reports, and post-approval regulatory submissions.
  • Collaborate with cross-functional teams such as CMC Regulatory Affairs, Drug Substance, Drug Product, Supply Chain, and Quality Assurance to ensure timely achievement of project milestones and objectives.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?